J&J Headed Back To The Future With “Legacy Growth” Plan
This article was originally published in The Gray Sheet
Executive SummaryJohnson & Johnson will set up four to six new businesses over the next decade as part of a "legacy growth" plan aimed at augmenting traditional development strategies
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.